Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
Extreme violent vomiting and stomach pain; Extreme violent vomiting and stomach pain; Case reference number US-BN-2025-001437 is a spontaneous case initially received from consumer via Communication (reference number: USBAV25-1384) on 21-Aug-2025 and concerns female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first, second and third dose of Vivotif (batch number: unknown) at an unknown dose, orally for unknown indication. On an unspecified date, unknown amount of time after the first dose, the patient took the fourth dose of Vivotif (batch number: unknown) at an unknown dose, orally. On an unspecified date, unknown amount of time after fourth dose of Vivotif vaccine in the night the patient experienced extreme violent vomiting and stomach pain. After four hours the symptoms went away, and the patient was able to sleep. As reported, the intensity of pain was described as 9. At the time of the initial report, it was unknown if the patient recovered from the events of 'vomiting' and 'stomach pain'. The reporter did not provide the seriousness of the events of 'vomiting' and 'stomach pain'. The reporter assessed the events were possibly related to the Vivotif vaccine. No further information was provided.; Reporter's Comments: This case concerns a female patient of unspecified age, who experienced non-serious events of abdominal pain upper and vomiting, on the same day after the patient receiving the fourth dose of Vivotif vaccine for an unknown indication. Vomiting is listed as per CCDS v8 and expected per USPI, whilst abdominal pain upper is listed and unexpected. Patient's medical history and concomitant medication details were not provided. Outcome is unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the reported events have been considered as related to Vivotif vaccine. This case is considered as non-serious.; Sender's Comments: This case concerns a female patient of unspecified age, who experienced non-serious events of abdominal pain upper and vomiting, on the same day after the patient receiving the fourth dose of Vivotif vaccine for an unknown indication. Vomiting is listed as per CCDS v8 and expected per USPI, whilst abdominal pain upper is listed and unexpected. Patient's medical history and concomitant medication details were not provided. Outcome is unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the reported events have been considered as related to Vivotif vaccine. This case is considered as non-serious.
Comments: None.